Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma.
Animals
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Chemoradiotherapy
Drug Repositioning
Enhancer of Zeste Homolog 2 Protein
/ metabolism
Eukaryotic Initiation Factor-4E
/ metabolism
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
IMP Dehydrogenase
/ metabolism
Mice
Molecular Targeted Therapy
Nasopharyngeal Carcinoma
/ metabolism
Nasopharyngeal Neoplasms
/ metabolism
Radiation-Sensitizing Agents
/ administration & dosage
Ribavirin
/ administration & dosage
Snail Family Transcription Factors
/ metabolism
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
05
06
2019
revised:
09
12
2019
accepted:
09
06
2020
pubmed:
2
7
2020
medline:
29
6
2021
entrez:
2
7
2020
Statut:
ppublish
Résumé
Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma with a proclivity for systemic dissemination, leading many patients to present with advanced stage disease and fail available treatments. There is a notable lack of targeted therapies for NPC, despite working knowledge of multiple proteins with integral roles in NPC cancer biology. These proteins include EZH2, Snail, eIF4E, and IMPDH, which are all overexpressed in NPC and correlated with poor prognosis. These proteins are known to be modulated by ribavirin, an FDA-approved hepatitis C antiviral that has recently been repurposed as a promising therapeutic in several solid and hematologic malignancies. Here, we investigated the potential of ribavirin as a targeted anticancer agent in five human NPC cell lines. Using cellular growth assays, flow cytometry, BrdU cell proliferation assays, scratch wound assays, and invasion assays, we show
Identifiants
pubmed: 32606016
pii: 1535-7163.MCT-19-0572
doi: 10.1158/1535-7163.MCT-19-0572
doi:
Substances chimiques
EIF4E protein, human
0
Eukaryotic Initiation Factor-4E
0
Radiation-Sensitizing Agents
0
SNAI1 protein, human
0
Snail Family Transcription Factors
0
Ribavirin
49717AWG6K
IMP Dehydrogenase
EC 1.1.1.205
IMPDH1 protein, human
EC 1.1.1.205
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1797-1808Subventions
Organisme : Howard Hughes Medical Institute
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.